Skip to content
MarketNewsAPI
Product Live news Screener Coverage Pricing
Docs Overview REST API WebSocket API MCP server
Resources Use cases Blog Changelog Status Compare Contact
Log in Get API key Dashboard
PRGO$15.78-0.14(-0.88%)Perrigo Announces Quarterly Dividend Perrigo Company plc (NYSE: PRGO), a leading provider of consumer self-care products, today announced that its Board of Directors has approved a...[12:30:00 PM ET]SNLGF$4.14-0.12(-2.82%)San Lorenzo Files Second Amended and Restated Offering Document[12:24:30 PM ET]FAGI$0.00+0.00(+2.63%)Full Alliance Group, Inc. (OTC: FAGI) The Future of Commerce Is Not Just Payments – YAHBEE & YAHIVE — It's Relationships[12:20:12 PM ET]DRTS$13.14-0.21(-1.57%)Alpha Tau Announces Inclusion in the Flagship TA-90 and TA-125 Indices of the Tel Aviv Stock Exchange[12:14:57 PM ET]FAGI$0.00+0.00(+2.63%)Full Alliance Group, Inc. (OTC: FAGI): Its Subsidiary Aquaox Pure Solutions Attracts New Business as Major Co[12:14:23 PM ET]UTMD$68.12-0.72(-1.05%)Utah Medical Products, Inc. Reports Corrected Results of Tender Offer[12:10:00 PM ET]KAI$271.38+5.58(+2.10%)Kadant to Hold Earnings Conference Call on Wednesday, November 4, 2026[12:02:20 PM ET]IPX$17.08+1.48(+9.53%)IperionX Webinar – Investor Update[12:00:00 PM ET]DDOG$261.37-17.04(-6.12%)Datadog Named a Leader in AIOps Platforms Research[12:00:00 PM ET]AGNT$3.93+0.00(+0.13%)Arizona's MHG Commercial Joins eXp Commercial With 18 Advisors and $435 Million in Closed Transactions[12:00:00 PM ET]

NRSN · NASDAQ

NeuroSense Therapeutics Ltd.

$2.15 -0.11 (-4.87%)

Company overview

NeuroSense Therapeutics Ltd. is a clinical-stage biotechnology company that focuses on the discovery and development of treatments for patients suffering from debilitating neurodegenerative diseases. Its lead product, PrimeC, is a novel oral formulation that has completed Phase IIa clinical trials for the treatment of amyotrophic lateral sclerosis. The company's preclinical pipeline includes StabiliC for the treatment of Parkinson's disease and CogniC for the treatment of Alzheimer's disease. NeuroSense Therapeutics Ltd. was incorporated in 2017 and is headquartered in Herzliya, Israel.

Sector
Healthcare
Industry
Biotechnology
Exchange
NASDAQ
Market cap
$4.1M
Employees
17
Headquarters
Herzliya
Website
neurosense-tx.com
CEO
Alon Ben-Noon
Listed
December 9, 2021
P/E
-5.68
Dividend yield
0.00%

Company financials

Revenue
$0.00
Gross profit
$0.00
Operating income
-$8.6M
EBITDA
-$8.6M
Net income
-$8.7M
EPS
-$0.38
Total assets
$1M
Total debt
$170,000
Earnings yield
-17.61%

Price chart

1.466.1410.8315.5220.21
NRSN 1D NASDAQ O2.33H2.37L2.21C2.26-0.11 (-4.64%)Vol6.28K

News

15-min delaySigned-out view is delayed 15 minutes. Log in on Pro for the live news desk.

Start 7-day free trial See live plans
Source
Date
Type
Ticker Type Headline Source Published
NRSNNeuroSense Therapeutics Ltd. Press release NeuroSense to Present Integrated Clinical and Biomarker Evidence Shaping PrimeC's Phase 3 Development at NEALS 2026 NeuroSense Therapeutics Ltd. PR Newswire
NRSNNeuroSense Therapeutics Ltd. Press release NeuroSense Files U.S. Patent Application for Traumatic Brain Injury NeuroSense Therapeutics Ltd. (NASDAQ: NRSN) ("NeuroSense" or the "Company"), a late-stage clinical biotechnology company developing treatments for... PR Newswire
NRSNNeuroSense Therapeutics Ltd. Press release NeuroSense Secures Nasdaq Hearing Date as PrimeC Approaches Key Regulatory and Funding Milestones NeuroSense Therapeutics Ltd. PR Newswire
NRSNNeuroSense Therapeutics Ltd. Stock news SpaceX, Qualcomm and 3 Stocks to Watch Heading Into Monday Benzinga
NRSNNeuroSense Therapeutics Ltd. Press release NeuroSense Provides Update on Nasdaq Listing Compliance PR Newswire
NRSNNeuroSense Therapeutics Ltd. Press release NeuroSense to Participate in the 5th Annual ROTH Healthcare Opportunities Conference PR Newswire
NRSNNeuroSense Therapeutics Ltd. Stock news NeuroSense Provides Business Update and Progress for the First Half of 2026 PRNewsWire
NRSNNeuroSense Therapeutics Ltd. Press release NeuroSense to Present at H.C. Wainwright 28th Annual Global Investment Conference PR Newswire
NRSNNeuroSense Therapeutics Ltd. Stock news This Occidental Petroleum Analyst Begins Coverage On A Bullish Note; Here Are Top 5 Initiations For Thursday Benzinga
NRSNNeuroSense Therapeutics Ltd. Press release NeuroSense Unveils Accelerated, Capital-Efficient Strategy to Advance PrimeC Toward Potential Approval in ALS PRNewsWire
NRSNNeuroSense Therapeutics Ltd. Press release NeuroSense Issues CEO Letter to Shareholders PRNewsWire
NRSNNeuroSense Therapeutics Ltd. Press release NeuroSense Completes PrimeC Pre-NDS Process and Advances Toward December 2026 Filing with Health Canada PRNewsWire
NRSNNeuroSense Therapeutics Ltd. Press release NeuroSense Advances PrimeC Toward New Drug Submission to Health Canada for ALS PRNewsWire
NRSNNeuroSense Therapeutics Ltd. Press release NeuroSense Announces Pricing of Insider-Led PIPE Financing PRNewsWire
NRSNNeuroSense Therapeutics Ltd. Stock news Brokerages Set NeuroSense Therapeutics Ltd. (NASDAQ:NRSN) Price Target at $8.50 Defense World
NRSNNeuroSense Therapeutics Ltd. Press release NeuroSense Granted Brazilian Patent Covering PrimeC Composition PRNewsWire
NRSNNeuroSense Therapeutics Ltd. Press release NeuroSense Therapeutics Announces Receipt of Nasdaq Notifications Regarding Minimum Bid Price and Market Value Requirements PRNewsWire
NRSNNeuroSense Therapeutics Ltd. Press release NeuroSense Therapeutics Reports Year End 2025 Financial Results and Provides Business Update PRNewsWire
NRSNNeuroSense Therapeutics Ltd. Press release NeuroSense Advances Toward Key Regulatory Milestones with Strengthened Data Package and Near-Term Alzheimer's Readout PRNewsWire
NRSNNeuroSense Therapeutics Ltd. Press release PrimeC New Data to Be Presented at AD/PD™ 2026 Conference PRNewsWire
See more
FAQ

Questions about NeuroSense Therapeutics Ltd.

What does NeuroSense Therapeutics Ltd. do?
NeuroSense Therapeutics Ltd. is a clinical-stage biotechnology company that focuses on the discovery and development of treatments for patients suffering from debilitating neurodegenerative diseases. Its lead product, PrimeC, is a novel oral formulation that has completed Phase IIa clinical trials for the treatment of amyotrophic lateral sclerosis. The company's preclinical pipeline includes StabiliC for the treatment of Parkinson's disease and CogniC for the treatment of Alzheimer's disease. NeuroSense Therapeutics Ltd. was incorporated in 2017 and is headquartered in Herzliya, Israel.
What is NRSN's market cap?
NeuroSense Therapeutics Ltd. (NRSN) is a listed stock with a live quote. The latest market cap on this page is $4.1M.
Where is NeuroSense Therapeutics Ltd. headquartered?
NeuroSense Therapeutics Ltd. is headquartered in Herzliya.
How do I get NRSN news from the API?
Call GET /v1/news?tickers=NRSN. Add type=news, type=press_release, or type=legal to take one feed. Pro keys search the full archive in real time. Free keys are delayed 15 minutes and return the last year. Signed-out visitors and Free accounts see that same year on this page. Pro sees the full archive.
How far back does NRSN news go?
Signed-out visitors and Free accounts see the last year of stock news, press releases, and legal notices for NRSN, 15 minutes behind, and each headline links to the publisher. Pro, including the 7-day trial, sees the full archive as headlines are ingested. A Free API key returns the last year. Pro keys search the full archive.
Is the NRSN price on this page from the API?
The price and daily change update during the US session for every visitor. That quote is context on this page. It is not part of the news API. The chart is one candle per session from the start of 2020. 1W, 1M, and 1Y group those sessions.
Can I use the Pro plan commercially?
No. The Pro plan cannot be used for commercial work. A product you sell, work you do for a client, or redistribution of the feed needs a custom plan and a license. Email [email protected].

Real-time stock news for $15 a month.

Start a 7-day Pro trial. A card is required. REST, WebSocket, and MCP are included, with 1,000 REST requests a day. You won't be charged during the trial. Unless you cancel, the card is billed for Pro when it ends.

Start 7-day free trial Read the docs